Glaukos Corp (GKOS) live share price

Glaukos Corp share price in USD $139.08 & INR ₹11,779.38

$139.08

▲

-4.57

(-3.18%)

View live Glaukos Corp share price in Dollar and Rupees. Guide to invest in Glaukos Corp from India. Also see the sentimental analysis on Indian investors investing in Glaukos Corp. Get details on the Indian mutual funds that are investing in Glaukos Corp. Get Analyst recommendations and forecasts along with all the Glaukos Corp's financials.

Glaukos Corp share price movements

$138.74
$142.24
$139.08
0.24%
Downside
Day's Volatility :2.46%
Upside
2.22%
$59.58
$146.86
$139.08
57.16%
Downside
52 Weeks Volatility :59.43%
Upside
5.3%

Glaukos Corp Returns

Period	Glaukos Corp	Sector (Health Care)	Index (Russel 2000)
3 Months	8.01%	-6.2%	0.0%
6 Months	28.68%	2.6%	0.0%
1 Year	124.42%	11.8%	0.0%
3 Years	246.56%	13.3%	-19.8%

Glaukos Corp Key Statistics

in dollars & INR

Market Capitalization	$7.8B
Revenue TTM	$360.3M
EBITDA	$-80.7M
Earnings Per Share (EPS)	$-2.93
Profit Margin	-41.51%
Quarterly Earnings Growth YOY	18.96%
Return On Equity TTM	-26.1%

How to invest in Glaukos Corp from India?

It is very easy for Indian residents to invest directly in Glaukos Corp from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Glaukos Corp stock in both rupees (INR) and dollars (USD). Search for Glaukos Corp or GKOS on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Glaukos Corp or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Glaukos Corp shares which would translate to 0.006 fractional shares of Glaukos Corp as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Glaukos Corp

Period: Sep 3, 2024 to Dec 2, 2024. Change in 30 Days versus previous period

Search volume for Glaukos Corp on INDmoney from India has grown in the last 30 days as on Dec 3, 2024. 0% more investors are searching Glaukos Corp in the last 30 days versus the previous period.

Global Institutional Holdings in Glaukos Corp

BlackRock Inc
14.58%
FMR Inc
11.94%
Vanguard Group Inc
10.65%
Wellington Management Company LLP
3.96%
State Street Corp
3.54%
Ameriprise Financial Inc
2.97%

Analyst Recommendation on Glaukos Corp

Buy

75%Buy

25%Hold

0%Sell

Based on 20 Wall street analysts offering stock ratings for Glaukos Corp(by analysts ranked 0 to 5 stars)

Based on 20 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Glaukos Corp

What analysts predicted

Upside of 2.4%

Current:

$139.08

Target:

$142.42

Insights on Glaukos Corp

Increasing Revenue
Revenue is up for the last 5 quarters, 78.04M → 96.67M (in $), with an average increase of 5.2% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -50.54M → -21.40M (in $), with an average increase of 136.1% per quarter

Glaukos Corp Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$181.3M	↑ 13.83%
Net Income	$-13.0M	↑ 13977.17%
Net Profit Margin	-7.14%	↓ 7.08%

	FY19	Y/Y Change
Revenue	$237.0M	↑ 30.73%
Net Income	$15.4M	↓ 219.1%
Net Profit Margin	6.51%	↑ 13.65%

	FY20	Y/Y Change
Revenue	$225.0M	↓ 5.07%
Net Income	$-120.3M	↓ 880.26%
Net Profit Margin	-53.5%	↓ 60.01%

	FY21	Y/Y Change
Revenue	$294.0M	↑ 30.7%
Net Income	$-49.6M	↓ 58.79%
Net Profit Margin	-16.87%	↑ 36.63%

	FY22	Y/Y Change
Revenue	$282.9M	↓ 3.79%
Net Income	$-99.2M	↑ 100.02%
Net Profit Margin	-35.07%	↓ 18.2%

	FY23	Y/Y Change
Revenue	$314.7M	↑ 11.26%
Net Income	$-134.7M	↑ 35.75%
Net Profit Margin	-42.79%	↓ 7.72%

	Q2 FY23	Q/Q Change
Revenue	$80.4M	↑ 8.8%
Net Income	$-32.8M	↓ 5.24%
Net Profit Margin	-40.81%	↑ 6.05%

	Q3 FY23	Q/Q Change
Revenue	$78.0M	↓ 2.92%
Net Income	$-30.4M	↓ 7.22%
Net Profit Margin	-39.01%	↑ 1.8%

	Q4 FY23	Q/Q Change
Revenue	$82.4M	↑ 5.53%
Net Income	$-36.8M	↑ 20.81%
Net Profit Margin	-44.65%	↓ 5.64%

	Q1 FY24	Q/Q Change
Revenue	$85.6M	↑ 3.95%
Net Income	$-40.8M	↑ 11.04%
Net Profit Margin	-47.7%	↓ 3.05%

	Q2 FY24	Q/Q Change
Revenue	$95.7M	↑ 11.76%
Net Income	$-50.5M	↑ 23.77%
Net Profit Margin	-52.82%	↓ 5.12%

	Q3 FY24	Q/Q Change
Revenue	$96.7M	↑ 1.02%
Net Income	$-21.4M	↓ 57.64%
Net Profit Margin	-22.15%	↑ 30.67%

	FY18	Y/Y Change
Total Assets	$207.0M	↑ 24.8%
Total Liabilities	$33.1M	↑ 19.82%

	FY19	Y/Y Change
Total Assets	$818.4M	↑ 295.42%
Total Liabilities	$145.1M	↑ 338.32%

	FY20	Y/Y Change
Total Assets	$1.0B	↑ 22.86%
Total Liabilities	$338.1M	↑ 132.93%

	FY21	Y/Y Change
Total Assets	$1.0B	↑ 4.4%
Total Liabilities	$462.5M	↑ 36.83%

	FY22	Y/Y Change
Total Assets	$1.0B	↓ 4.51%
Total Liabilities	$472.4M	↑ 2.13%

	FY23	Y/Y Change
Total Assets	$940.4M	↓ 6.18%
Total Liabilities	$478.6M	↑ 1.33%

	Q2 FY23	Q/Q Change
Total Assets	$956.7M	↓ 1.63%
Total Liabilities	$467.9M	↑ 0.83%

	Q3 FY23	Q/Q Change
Total Assets	$948.6M	↓ 0.85%
Total Liabilities	$471.0M	↑ 0.65%

	Q4 FY23	Q/Q Change
Total Assets	$940.4M	↓ 0.87%
Total Liabilities	$478.6M	↑ 1.63%

	Q1 FY24	Q/Q Change
Total Assets	$933.3M	↓ 0.75%
Total Liabilities	$482.6M	↑ 0.83%

	Q2 FY24	Q/Q Change
Total Assets	$919.7M	↓ 1.46%
Total Liabilities	$254.5M	↓ 47.26%

	Q3 FY24	Q/Q Change
Total Assets	$926.5M	↑ 0.75%
Total Liabilities	$258.0M	↑ 1.38%

	FY18	Y/Y Change
Operating Cash Flow	$18.9M	↓ 26.05%
Investing Cash Flow	$-26.4M	↑ 125.12%
Financing Cash Flow	$21.6M	↑ 362.31%

	FY19	Y/Y Change
Operating Cash Flow	$-369.0K	↓ 101.96%
Investing Cash Flow	$43.4M	↓ 264.49%
Financing Cash Flow	$-9.6M	↓ 144.7%

	FY20	Y/Y Change
Operating Cash Flow	$-23.0M	↑ 6129.81%
Investing Cash Flow	$-205.1M	↓ 572.21%
Financing Cash Flow	$262.5M	↓ 2822.05%

	FY21	Y/Y Change
Operating Cash Flow	$24.7M	↓ 207.48%
Investing Cash Flow	$-58.2M	↓ 71.6%
Financing Cash Flow	$39.3M	↓ 85.05%

	FY22	Y/Y Change
Operating Cash Flow	$-33.1M	↓ 233.9%
Investing Cash Flow	$44.8M	↓ 176.9%
Financing Cash Flow	$6.3M	↓ 84.08%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-8.2M	↓ 73.47%
Investing Cash Flow	$26.0M	↓ 287.62%
Financing Cash Flow	$-880.0K	↓ 176.39%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-8.2M	↑ 0.09%
Investing Cash Flow	$14.9M	↓ 42.6%
Financing Cash Flow	$7.5M	↓ 948.52%

Glaukos Corp Technicals Summary

Sell

Neutral

Buy

Glaukos Corp is currently in a neutral trading position according to technical analysis indicators.

Glaukos Corp Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Glaukos Corp	9.34%	28.68%	124.42%	246.56%	140.7%
Stryker Corporation	6.88%	14.66%	34.78%	54.14%	92.98%
Boston Scientific Corp.	7.01%	19.42%	65.53%	122.75%	109.57%
Edwards Lifesciences Corp.	7.34%	-18.37%	3.14%	-36.27%	-11.9%
Abbott Laboratories	0.95%	14.83%	12.91%	-10.34%	39.34%
Medtronic Plc	-3.1%	3.93%	8.5%	-21.5%	-22.87%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Glaukos Corp	NA	NA	1.64	-1.82	-0.26	-0.08	NA	12.13
Stryker Corporation	42.03	41.65	2.71	12.06	0.19	0.07	0.01	52.86
Boston Scientific Corp.	74.93	75.0	1.65	2.46	0.09	0.05	NA	14.05
Edwards Lifesciences Corp.	27.55	27.55	6.61	2.53	0.19	0.11	NA	16.18
Abbott Laboratories	36.1	36.16	2.31	4.68	0.15	0.06	0.02	22.94
Medtronic Plc	26.38	26.38	1.56	5.2	0.08	0.04	0.03	38.29

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Glaukos Corp	Buy	$7.9B	140.7%	NA	-41.51%
Stryker Corporation	Buy	$149.5B	92.98%	42.03	16.34%
Boston Scientific Corp.	Buy	$133.7B	109.57%	74.93	11.26%
Edwards Lifesciences Corp.	Buy	$42.5B	-11.9%	27.55	65.86%
Abbott Laboratories	Buy	$206.3B	39.34%	36.1	13.99%
Medtronic Plc	Buy	$110.6B	-22.87%	26.38	12.06%

Glaukos Corp Dividend announcements

Glaukos Corp Earnings
Glaukos Corp’s price-to-earnings ratio stands at None
Read More

About Glaukos Corp

glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde

Organization	Glaukos Corp
Employees	907
CEO	Mr. Thomas William Burns
Industry	Health Technology

Important FAQs about investing in Glaukos Corp from India :

What is Glaukos Corp share price today?

Glaukos Corp (GKOS) share price today is $139.08.

Can Indians buy Glaukos Corp shares?

Yes, Indians can invest in the Glaukos Corp (GKOS) from India.

With INDmoney, you can buy Glaukos Corp at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Glaukos Corp at zero transaction cost.

How can I buy Glaukos Corp shares from India?

It is very easy to buy Glaukos Corp from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Glaukos Corp be purchased?

Yes, you can buy fractional shares of Glaukos Corp with INDmoney app.

What are the documents required to start investing in Glaukos Corp stocks?

To start investing in Glaukos Corp, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.